Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AbbVie Reports Third-Quarter 2022 Financial Results


      News provided by

      AbbVie

      Oct 28, 2022, 07:44 ET

      Share this article

      Share this article


      • Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Diluted EPS of $3.66, an Increase of 29.3 Percent; These Results Include an Unfavorable Impact of $0.02 Per Share related to Acquired IPR&D and Milestones Expense 1
      • Delivers Third-Quarter Net Revenues of $14.812 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.4 Percent Operationally
      • Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.651 Billion, an Increase of 14.6 Percent on a Reported Basis, or 16.4 Percent on an Operational Basis; U.S. Humira Net Revenues Were $4.956 Billion, an Increase of 7.4 Percent; Internationally, Humira Net Revenues Were $603 Million, a Decrease of 25.9 Percent on a Reported Basis, or 16.8 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.397 Billion; Global Rinvoq Net Revenues Were $695 Million
      • Third-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.650 Billion, a Decrease of 11.7 Percent on a Reported Basis, or 9.9 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $1.135 Billion, a Decrease of 17.4 Percent, with U.S. Net Revenues of $849 Million and International Profit Sharing of $286 Million; Global Venclexta Net Revenues Were $515 Million
      • Third-Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.672 Billion, an Increase of 6.7 Percent on a Reported Basis, or 8.3 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $699 Million; Vraylar Net Revenues Were $554 Million
      • Third-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.301 Billion, an Increase of 4.0 Percent on a Reported Basis, or 8.1 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $637 Million; Global Juvederm Net Revenues Were $352 Million
      • Confirms Midpoint of 2022 Adjusted Diluted EPS Guidance Range and Narrows Range from $13.76 - $13.96 to $13.84 - $13.88, which Includes an Unfavorable Impact of $0.25 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2022
      • Announces 2023 Dividend Increase of 5.0 Percent, Beginning with Dividend Payable in February 2023

      NORTH CHICAGO, Ill., Oct. 28, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2022.

      "We continue to see strong momentum from our key immunology assets, Skyrizi and Rinvoq, and this performance – combined with strength from other growth drivers within our diverse portfolio – has mitigated the impact of temporary economic headwinds on our aesthetics products to deliver another quarter of strong results," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "Based upon our performance and confidence in AbbVie's long-term outlook, we are once again meaningfully raising our dividend."

      Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

      1 Beginning in the first quarter 2022, AbbVie includes the impact of upfront and milestone payments related to collaborations, licensing agreements and other asset acquisitions in its reported non-GAAP financial measures.

      Third-Quarter Results

      • Worldwide net revenues were $14.812 billion, an increase of 3.3 percent on a GAAP basis, or 5.4 percent on an operational basis.

      • Global net revenues from the immunology portfolio were $7.651 billion, an increase of 14.6 percent on a reported basis, or 16.4 percent on an operational basis.
        • Global Humira net revenues of $5.559 billion increased 2.5 percent on a reported basis, or 3.9 percent on an operational basis. U.S. Humira net revenues were $4.956 billion, an increase of 7.4 percent. Internationally, Humira net revenues were $603 million, a decrease of 25.9 percent on a reported basis, or 16.8 percent on an operational basis, due to biosimilar competition.
        • Global Skyrizi net revenues were $1.397 billion, an increase of 75.4 percent on a reported basis, or 78.3 percent on an operational basis.
        • Global Rinvoq net revenues were $695 million, an increase of 53.5 percent on a reported basis, or 59.3 percent on an operational basis.
      • Global net revenues from the hematologic oncology portfolio were $1.650 billion, a decrease of 11.7 percent on a reported basis, or 9.9 percent on an operational basis.
        • Global Imbruvica net revenues were $1.135 billion, a decrease of 17.4 percent, with U.S. net revenues of $849 million and international profit sharing of $286 million.
        • Global Venclexta net revenues were $515 million, an increase of 4.5 percent on a reported basis, or 11.3 percent on an operational basis.
      • Global net revenues from the neuroscience portfolio were $1.672 billion, an increase of 6.7 percent on a reported basis, or 8.3 percent on an operational basis.
        • Global Botox Therapeutic net revenues were $699 million, an increase of 8.2 percent on a reported basis, or 10.0 percent on an operational basis.
        • Vraylar net revenues were $554 million, an increase of 20.2 percent.
        • Global Ubrelvy net revenues were $160 million.
      • Global net revenues from the aesthetics portfolio were $1.301 billion, an increase of 4.0 percent on a reported basis, or 8.1 percent on an operational basis.
        • Global Botox Cosmetic net revenues were $637 million, an increase of 16.9 percent on a reported basis, or 21.6 percent on an operational basis.
        • Global Juvederm net revenues were $352 million, a decrease of 0.6 percent on a reported basis, or an increase of 5.3 percent on an operational basis.
      • On a GAAP basis, the gross margin ratio in the third quarter was 66.1 percent. The adjusted gross margin ratio was 85.4 percent.
      • On a GAAP basis, selling, general and administrative (SG&A) expense was 22.3 percent of net revenues. The adjusted SG&A expense was 20.9 percent of net revenues.
      • On a GAAP basis, research and development (R&D) expense was 10.9 percent of net revenues. The adjusted R&D expense was 10.8 percent of net revenues.
      • Acquired IPR&D and milestones expense was 0.3 percent of net revenues.
      • On a GAAP basis, the operating margin in the third quarter was 31.1 percent. The adjusted operating margin was 53.4 percent.
      • Net interest expense was $497 million.
      • On a GAAP basis, the tax rate in the quarter was 10.2 percent. The adjusted tax rate was 12.9 percent.
      • Diluted EPS in the third quarter was $2.21 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.66. These results include an unfavorable impact of $0.02 per share related to acquired IPR&D and milestones expense.

      Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

      Recent Events

      • AbbVie announced the U.S. Food and Drug Administration (FDA) approved Rinvoq (upadacitinib, 15 mg, once daily) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy. The approval is supported by data from the SELECT-AXIS 2 clinical trial, in which Rinvoq delivered rapid and meaningful disease control as well as significant improvement in signs and symptoms of nr-axSpA. This approval marks the sixth FDA approved indication for Rinvoq in chronic immune-mediated diseases.
      • AbbVie announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Skyrizi (risankizumab) for the treatment of adults with moderately to severely active Crohn's disease (CD) who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. The positive opinion is based on results from three Phase 3 studies in which Skyrizi demonstrated significant improvements in clinical remission and endoscopic response, compared to placebo, as both induction and maintenance therapy. If the CHMP recommendation is accepted by the European Commission (EC), this would mark the third indication for Skyrizi in the European Union. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
      • At the United European Gastroenterology (UEG) Week 2022, AbbVie shared 17 abstracts, including seven oral presentations, from a broad range of studies in inflammatory bowel disease (IBD). Highlights included final analyses from the U-ACHIEVE Phase 3 maintenance study of Rinvoq in moderately to severely active ulcerative colitis (UC), data from the U-EXCEL Phase 3 study evaluating the efficacy and safety of Rinvoq as induction therapy for use in adults with moderately to severely active CD as well as data evaluating Skyrizi for use in patients with moderate to severe CD.
      • At the American College of Gastroenterology (ACG) Annual Scientific Meeting, AbbVie presented 26 abstracts that illustrate AbbVie's commitment to providing research and innovative solutions that support patients with high disease burden and unmet need. Key presentations focused on the treatment of moderate to severe CD, including late-breaking Phase 3 data from the Rinvoq 52 week maintenance trial, as well as efficacy and safety outcomes from the Skyrizi pivotal clinical program.
      • At the European Academy of Dermatology and Venereology (EADV) Congress, AbbVie presented 23 abstracts from across its dermatology portfolio that underscore AbbVie's commitment to advancing research in dermatology for people living with immune-mediated skin diseases such as psoriasis (PsO), psoriatic arthritis (PsA), atopic dermatitis (AD) and vitiligo. Presentations included long-term efficacy and safety results, including real-world data, from studies of Skyrizi in moderate to severe PsO and active PsA as well as data from the largest-of-its-kind study that demonstrate the real-world burden of AD.
      • AbbVie announced that the FDA approved the use of Imbruvica (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. The approval marks the first approved treatment option for children with cGVHD under 12 years of age and the only Bruton's tyrosine kinase inhibitor (BTKi) treatment for a pediatric patient population. Imbruvica is jointly developed and commercialized with Janssen Biotech, Inc.
      • At the International Parkinson and Movement Disorder Society's (MDS) International Congress, AbbVie presented 13 abstracts across multiple disease states that highlighted AbbVie's continued commitment to advancing the management of movement disorders. Highlights included results from the Phase 3 M15-736 trial evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in people with advanced Parkinson's disease (PD) as well as data on the real-world efficacy of Botox (onabotulinumtoxinA) for the treatment of spasticity and treatment of cervical dystonia.
      • At the Migraine Trust International Symposium (MTIS), AbbVie shared 13 abstracts, including 4 oral presentations, from a wide range of studies across its migraine portfolio that underscore AbbVie's leadership and commitment to people living with migraine. Highlights included Phase 3 PROGRESS study results evaluating Qulipta (atogepant) for the preventive treatment of chronic migraine as well as data from studies evaluating Botox and Ubrelvy (ubrogepant) in the treatment of migraine.
      • Allergan Aesthetics announced that the FDA approved Juvederm Volux XC for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. Juvederm Volux XC is the first and only hyaluronic acid (HA) filler to receive FDA approval for jawline definition.
      • At the American Society for Dermatologic Surgery (ASDS), Allergan Aesthetics shared data from across its facial injectables, body contouring and skincare portfolio that highlighted Allergan Aesthetics' continued commitment to advancing aesthetic medicine. Highlights included analyses of 15 years of post-marketing surveillance data that demonstrated the global reported rate of delayed-onset nodules associated with dermal fillers on the Vycross technology platform is low, as well as results from three clinical studies showcasing a customizable platform with patent-pending LTN Complex, to address the appearance of facial hyperpigmentation.
      • AbbVie announced the acquisition of DJS Antibodies (DJS), a biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins. The acquisition includes DJS' lead program DJS-002, a potential first-in-class LPAR1 antagonist antibody in preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases as well as the company's proprietary HEPTAD platform.

      Full-Year 2022 Outlook

      AbbVie is confirming the midpoint of its full-year 2022 adjusted diluted EPS guidance range and narrowing the range from $13.76 - $13.96 to $13.84 - $13.88, which includes an unfavorable impact of $0.25 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2022. The company's 2022 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2022, as both cannot be reliably forecasted.

      Company Declares Dividend Increase of 5.0 Percent

      AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.41 per share to $1.48 per share beginning with the dividend payable on February 15, 2023 to shareholders of record as of January 13, 2023. This reflects an increase of approximately 5.0 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013, AbbVie has increased its quarterly dividend by 270 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

      About AbbVie

      AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

      Conference Call

      AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our third-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central time.

      Non-GAAP Financial Results

      Financial results for 2022 and 2021 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. Beginning in the first quarter of 2022, the company includes the impact of upfront and milestone payments related to collaborations, licensing agreements, and other asset acquisitions in its reported non-GAAP financial measures. Prior periods have been revised to conform to the current period presentation. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.

      Forward-Looking Statements

      Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the failure to realize the expected benefits of AbbVie's acquisition of Allergan or to promptly and effectively integrate Allergan's business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

      AbbVie Inc.
      Key Product Revenues
      Quarter Ended September 30, 2022
      (Unaudited) 








      % Change vs. 3Q21


      Net Revenues (in millions)


      Reported


      Operationala


      U.S.


      Int'l.


      Total


      U.S.


      Int'l.


      Total


      Int'l.


      Total

      NET REVENUES

      $11,763


      $3,049


      $14,812


      4.3 %


      (0.4) %


      3.3 %


      9.6 %


      5.4 %

















      Immunology

      6,682


      969


      7,651


      18.5


      (6.3)


      14.6


      5.6


      16.4

      Humira

      4,956


      603


      5,559


      7.4


      (25.9)


      2.5


      (16.8)


      3.9

      Skyrizi

      1,221


      176


      1,397


      79.8


      50.1


      75.4


      70.0


      78.3

      Rinvoq

      505


      190


      695


      44.7


      82.9


      53.5


      >100.0


      59.3

















      Hematologic Oncology                                      

      1,108


      542


      1,650


      (17.7)


      3.9


      (11.7)


      10.3


      (9.9)

      Imbruvicab

      849


      286


      1,135


      (23.5)


      7.6


      (17.4)


      7.6


      (17.4)

      Venclexta

      259


      256


      515


      9.2


      0.1


      4.5


      13.2


      11.3

















      Aesthetics

      760


      541


      1,301


      (7.4)


      25.6


      4.0


      37.4


      8.1

      Botox Cosmetic

      370


      267


      637


      4.1


      41.0


      16.9


      54.5


      21.6

      Juvederm Collection

      125


      227


      352


      (21.9)


      16.9


      (0.6)


      27.7


      5.3

      Other Aesthetics

      265


      47


      312


      (13.1)


      (0.8)


      (11.4)


      8.3


      (10.2)

















      Neuroscience

      1,464


      208


      1,672


      8.6


      (5.0)


      6.7


      6.3


      8.3

      Botox Therapeutic

      584


      115


      699


      9.2


      3.6


      8.2


      14.2


      10.0

      Vraylar

      554


      —


      554


      20.1


      n/a


      20.2


      n/a


      20.2

      Duodopa

      22


      88


      110


      (4.9)


      (15.0)


      (13.1)


      (2.6)


      (3.0)

      Ubrelvy

      160


      —


      160


      (1.4)


      n/a


      (1.4)


      n/a


      (1.4)

      Qulipta

      62


      —


      62


      n/m


      n/a


      n/m


      n/a


      n/m

      Other Neuroscience

      82


      5


      87


      (50.5)


      10.2


      (49.0)


      14.1


      (48.9)

















      Eye Care

      362


      261


      623


      (38.1)


      (9.1)


      (28.6)


      1.3


      (25.2)

      Lumigan/Ganfort

      59


      62


      121


      (4.4)


      (18.7)


      (12.2)


      (8.7)


      (6.7)

      Alphagan/Combigan

      37


      36


      73


      (58.2)


      (8.9)


      (43.0)


      2.9


      (39.4)

      Restasis

      132


      10


      142


      (56.7)


      (30.7)


      (55.6)


      (37.7)


      (55.9)

      Other Eye Care

      134


      153


      287


      3.7


      (2.7)


      0.1


      9.1


      6.6

















      Other Key Products                                                                                        

      788


      202


      990


      5.5


      (19.4)


      (0.7)


      (9.1)


      1.9

      Mavyret

      190


      193


      383


      3.5


      (20.6)


      (10.2)


      (10.3)


      (4.4)

      Creon

      336


      —


      336


      8.5


      n/a


      8.5


      n/a


      8.5

      Linzess/Constella

      262


      9


      271


      3.4


      16.0


      3.8


      25.8


      4.1



      a

      "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

      b 

      Reflects profit sharing for Imbruvica international revenues.

      n/a = not applicable

      n/m = not meaningful

      AbbVie Inc.

      Key Product Revenues

      Nine Months Ended September 30, 2022

      (Unaudited)









      % Change vs. 9M21


      Net Revenues (in millions)


      Reported


      Operationala


      U.S.


      Int'l.


      Total


      U.S.


      Int'l.


      Total


      Int'l.


      Total

      NET REVENUES

      $33,521


      $9,412


      $42,933


      5.3 %


      (0.7) %


      3.9 %


      6.7 %


      5.6 %

















      Immunology

      17,922


      3,077


      20,999


      16.4


      (2.2)


      13.3


      6.6


      14.8

      Humira

      13,613


      2,045


      15,658


      6.5


      (20.9)


      1.9


      (14.3)


      3.0

      Skyrizi

      3,081


      508


      3,589


      78.6


      59.3


      75.6


      75.1


      78.1

      Rinvoq

      1,228


      524


      1,752


      38.0


      >100.0


      54.5


      >100.0


      59.3

















      Hematologic Oncology                                      

      3,325


      1,621


      4,946


      (14.5)


      10.7


      (7.6)


      15.6


      (6.3)

      Imbruvicab

      2,585


      868


      3,453


      (19.4)


      6.3


      (14.2)


      6.3


      (14.2)

      Venclexta

      740


      753


      1,493


      8.1


      16.2


      12.1


      27.3


      17.5

















      Aesthetics

      2,489


      1,557


      4,046


      0.6


      15.1


      5.8


      23.1


      8.6

      Botox Cosmetic

      1,232


      741


      1,973


      20.0


      27.9


      22.8


      36.8


      26.0

      Juvederm Collection

      420


      686


      1,106


      (12.3)


      9.9


      0.3


      17.6


      4.6

      Other Aesthetics

      837


      130


      967


      (13.4)


      (12.8)


      (13.4)


      (7.2)


      (12.7)

















      Neuroscience

      4,175


      643


      4,818


      15.2


      (1.1)


      12.8


      7.9


      14.2

      Botox Therapeutic

      1,641


      350


      1,991


      13.1


      6.5


      11.9


      15.0


      13.5

      Vraylar

      1,473


      —


      1,473


      18.9


      n/a


      18.9


      n/a


      18.9

      Duodopa

      72


      279


      351


      (2.4)


      (9.8)


      (8.4)


      —


      (0.5)

      Ubrelvy

      483


      —


      483


      31.0


      n/a


      31.0


      n/a


      31.0

      Qulipta

      106


      —


      106


      n/m


      n/a


      n/m


      n/a


      n/m

      Other Neuroscience

      400


      14


      414


      (18.3)


      10.3


      (17.6)


      13.1


      (17.5)

















      Eye Care

      1,265


      846


      2,111


      (26.9)


      (3.5)


      (19.0)


      5.4


      (16.0)

      Lumigan/Ganfort

      186


      205


      391


      (7.1)


      (10.8)


      (9.0)


      (2.9)


      (4.8)

      Alphagan/Combigan

      161


      111


      272


      (40.8)


      (5.1)


      (30.0)


      4.9


      (27.0)

      Restasis

      518


      38


      556


      (41.3)


      (10.1)


      (39.9)


      (2.8)


      (39.6)

      Other Eye Care

      400


      492


      892


      6.3


      0.9


      3.3


      10.1


      8.5

















      Other Key Products                                                                                        

      2,245


      623


      2,868


      4.5


      (16.9)


      (1.0)


      (8.6)


      1.2

      Mavyret

      562


      599


      1,161


      0.9


      (17.5)


      (9.5)


      (9.1)


      (4.7)

      Creon

      941


      —


      941


      9.0


      n/a


      9.0


      n/a


      9.0

      Linzess/Constella

      742


      24


      766


      2.0


      3.2


      2.0


      9.6


      2.2



      a

      "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

      b

      Reflects profit sharing for Imbruvica international revenues.

      n/a = not applicable

      n/m = not meaningful

      AbbVie Inc.

      Consolidated Statements of Earnings

      (Unaudited)


      (in millions, except per share data)

      Third Quarter

      Ended September 30


      Nine Months

      Ended September 30


      2022


      2021


      2022


      2021

      Net revenues

      $       14,812


      $       14,342


      $       42,933


      $        41,311

      Cost of products sold

      5,022


      4,390


      13,244


      13,126

      Selling, general and administrative

      3,304


      3,083


      11,843


      9,089

      Research and developmenta

      1,614


      1,661


      4,720


      5,095

      Acquired IPR&D and milestonesa

      40


      402


      454


      719

      Other operating expense, net

      229


      500


      57


      432

      Total operating costs and expenses

      10,209


      10,036


      30,318


      28,461









      Operating earnings

      4,603


      4,306


      12,615


      12,850









      Interest expense, net

      497


      585


      1,568


      1,813

      Net foreign exchange loss

      36


      12


      108


      35

      Other expense (income), net

      (330)


      21


      427


      2,284

      Earnings before income tax expense

      4,400


      3,688


      10,512


      8,718

      Income tax expense

      448


      508


      1,139


      1,214

      Net earnings

      3,952


      3,180


      9,373


      7,504

      Net earnings attributable to noncontrolling interest

      3


      1


      10


      6

      Net earnings attributable to AbbVie Inc.

      $          3,949


      $          3,179


      $          9,363


      $          7,498









      Diluted earnings per share attributable to AbbVie Inc.                                                                                       

      $            2.21


      $            1.78


      $            5.24


      $            4.19









      Adjusted diluted earnings per shareb

      $            3.66


      $            2.83


      $          10.18


      $            8.75









      Weighted-average diluted shares outstanding

      1,776


      1,777


      1,777


      1,776



      a

      During the three months ended March 31, 2022, AbbVie changed its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development expense, are now presented as acquired IPR&D and milestones expense. The reclassification decreased research and development expense and increased acquired IPR&D and milestones expense by $12 million for the three months and $162 million for the nine months ended September 30, 2021. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been revised to conform to the current period presentation. The reclassification had no impact on total operating costs and expenses, operating earnings, net earnings, net earnings attributable to AbbVie, Inc., earnings per share, or total equity.



      b

      Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      (Unaudited)


      1.     Specified items impacted results as follows:







      Quarter Ended September 30, 2022

      (in millions, except per share data)





      Earnings


      Diluted






      Pre-tax


      After-taxa


      EPS

      As reported (GAAP)





      $              4,400


      $              3,949


      $                2.21

      Adjusted for specified items:










      Intangible asset amortization





      2,024


      1,673


      0.94

      Intangible asset impairment





      770


      604


      0.34

      Acquisition and integration costs





      348


      348


      0.20

      Change in fair value of contingent consideration                                                                                           





      (214)


      (218)


      (0.12)

      Litigation matters





      110


      94


      0.05

      Other





      58


      78


      0.04

      As adjusted (non-GAAP)





      $              7,496


      $              6,528


      $                3.66


      a     Represents net earnings attributable to AbbVie Inc. 


      Acquisition and integration costs include costs related to the Allergan acquisition. Other primarily includes restructuring charges associated with streamlining global operations.


      Beginning in the first quarter of 2022, the company includes acquired IPR&D and milestones expense in its reported non-GAAP financial measures. Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2022 included acquired IPR&D and milestones expense of $40 million on a pre-tax and after-tax basis, representing an unfavorable impact of $0.02 to both diluted EPS and adjusted diluted EPS.


      2.     The impact of the specified items by line item was as follows:



      Quarter Ended September 30, 2022

      (in millions)

      Cost of
      products
      sold


      SG&A


      R&D


      Other
      operating
      expense,
      net


      Other
      expense
      (income),
      net

      As reported (GAAP)

      $         5,022


      $        3,304


      $              1,614


      $                 229


      $                (330)

      Adjusted for specified items:










      Intangible asset amortization

      (2,024)


      —


      —


      —


      —

      Intangible asset impairment

      (770)


      —


      —


      —


      —

      Acquisition and integration costs

      (22)


      (91)


      (6)


      (229)


      —

      Change in fair value of contingent consideration                               

      —


      —


      —


      —


      214

      Litigation matters

      —


      (110)


      —


      —


      —

      Other

      (39)


      (14)


      (1)


      —


      (4)

      As adjusted (non-GAAP)

      $          2,167


      $        3,089


      $              1,607


      $                    —


      $                (120)











      3.     The adjusted tax rate for the third quarter of 2022 was 12.9 percent, as detailed below:











      Quarter Ended September 30, 2022

      (dollars in millions)





      Pre-tax
      earnings


      Income taxes


      Tax rate

      As reported (GAAP)





      $              4,400


      $                  448


      10.2 %

      Specified items





      3,096


      517


      16.7 %

      As adjusted (non-GAAP)





      $              7,496


      $                  965


      12.9 %

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      (Unaudited)


      1.     Specified items impacted results as follows:





      Quarter Ended September 30, 2021

      (in millions, except per share data)



      Earnings


      Diluted




      Pre-tax


      After-taxa


      EPS

      As reported (GAAP)



      $              3,688


      $              3,179


      $                1.78

      Adjusted for specified items:








      Intangible asset amortization



      1,904


      1,585


      0.88

      Acquisition and integration costs



      176


      166


      0.09

      Change in fair value of contingent consideration                                                                                                    



      98


      98


      0.06

      Other



      48


      29


      0.02

      As adjusted (non-GAAP)



      $              5,914


      $              5,057


      $                2.83


      a     Represents net earnings attributable to AbbVie Inc.


      Acquisition and integration costs reflect Allergan-related integration costs. Other primarily includes restructuring charges associated with streamlining global operations and COVID-19 related expenses.


      Beginning in the first quarter of 2022, the company includes acquired IPR&D and milestones expense in its reported non-GAAP financial measures. Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2021 included acquired IPR&D and milestones expense of $402 million on a pre-tax and $396 million on an after-tax basis, as well as other operating expense related to the Calico collaboration of $500 million on a pre-tax and after-tax basis, representing an unfavorable impact of $0.50 to both diluted EPS and adjusted diluted EPS.


      2.     The impact of the specified items by line item was as follows: 



      Quarter Ended September 30, 2021

      (in millions)

      Cost of
      products
      sold


      SG&A


      R&D


      Other
      expense
      (income),
      net

      As reported (GAAP)

      $        4,390


      $              3,083


      $              1,661


      $                   21

      Adjusted for specified items:








      Intangible asset amortization

      (1,904)


      —


      —


      —

      Acquisition and integration costs

      (49)


      (105)


      (22)


      —

      Change in fair value of contingent consideration                                                           

      —


      —


      —


      (98)

      Other

      (24)


      (17)


      (7)


      —

      As adjusted (non-GAAP)

      $        2,413


      $              2,961


      $              1,632


      $                  (77)


       3.     The adjusted tax rate for the third quarter of 2021 was 14.5 percent, as detailed below:





      Quarter Ended September 30, 2021

      (dollars in millions)



      Pre-tax
      earnings


      Income taxes


      Tax rate

      As reported (GAAP)



      $              3,688


      $                 508


      13.8 %

      Specified items



      2,226


      348


      15.6 %

      As adjusted (non-GAAP)



      $              5,914


      $                 856


      14.5 %

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      (Unaudited)


      1.     Specified items impacted results as follows:







      Nine Months Ended September 30, 2022

      (in millions, except per share data)





      Earnings


      Diluted






      Pre-tax


      After-taxa


      EPS

      As reported (GAAP)





      $           10,512


      $              9,363


      $                5.24

      Adjusted for specified items:










      Intangible asset amortization





      5,728


      4,794


      2.69

      Intangible asset impairment





      770


      604


      0.34

      Acquisition and integration costs





      595


      567


      0.32

      Change in fair value of contingent consideration                                                                                     





      647


      657


      0.37

      Pylera divestiture





      (172)


      (126)


      (0.07)

      Litigation matters





      2,497


      2,021


      1.13

      Other





      281


      295


      0.16

      As adjusted (non-GAAP)





      $           20,858


      $           18,175


      $              10.18


      a     Represents net earnings attributable to AbbVie Inc.


      Acquisition and integration costs include costs related to the Allergan acquisition. Litigation matters primarily include a charge related to a potential settlement of litigation involving Allergan's past sales of opioid products. Other primarily includes restructuring charges associated with streamlining global operations.


      Beginning in the first quarter of 2022, the company includes acquired IPR&D and milestones expense in its reported non-GAAP financial measures. Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2022 included acquired IPR&D and milestones expense of $454 million on a pre-tax and $439 million on an after-tax basis, representing an unfavorable impact of $0.25 to both diluted EPS and adjusted diluted EPS.


      2.     The impact of the specified items by line item was as follows: 



      Nine Months Ended September 30, 2022

      (in millions)

      Cost of
      products
      sold


      SG&A


      R&D


      Other
      operating
      expense,
      net


      Other
      expense
      (income),
      net

      As reported (GAAP)

      $        13,244


      $      11,843


      $            4,720


      $                   57


      $                427

      Adjusted for specified items:










      Intangible asset amortization

      (5,728)


      —


      —


      —


      —

      Intangible asset impairment

      (770)


      —


      —


      —


      —

      Acquisition and integration costs

      (84)


      (263)


      (19)


      (229)


      —

      Change in fair value of contingent consideration                       

      —


      —


      —


      —


      (647)

      Pylera divestiture

      —


      —


      —


      172


      —

      Litigation matters

      —


      (2,497)


      —


      —


      —

      Other

      (160)


      (107)


      (7)


      —


      (7)

      As adjusted (non-GAAP)

      $          6,502


      $        8,976


      $             4,694


      $                    —


      $                (227)


      3.     The adjusted tax rate for the first nine months of 2022 was 12.8 percent, as detailed below:







      Nine Months Ended September 30, 2022

      (dollars in millions)





      Pre-tax
      earnings


      Income taxes


      Tax rate

      As reported (GAAP)





      $           10,512


      $              1,139


      10.8 %

      Specified items





      10,346


      1,534


      14.8 %

      As adjusted (non-GAAP)





      $           20,858


      $              2,673


      12.8 %

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      (Unaudited)


      1.     Specified items impacted results as follows:







      Nine Months Ended September 30, 2021

      (in millions, except per share data)





      Earnings


      Diluted






      Pre-tax


      After-taxa


      EPS

      As reported (GAAP)





      $              8,718


      $              7,498


      $                4.19

      Adjusted for specified items:










      Intangible asset amortization





      5,912


      4,929


      2.77

      Acquisition and integration costs





      535


      427


      0.23

      Change in fair value of contingent consideration                                                                                       





      2,447


      2,445


      1.38

      Litigation matters





      107


      86


      0.05

      Other





      319


      255


      0.13

      As adjusted (non-GAAP)





      $           18,038


      $           15,640


      $                8.75


       a    Represents net earnings attributable to AbbVie Inc.


      Acquisition and integration costs reflect integration costs as well as amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition. Other primarily includes the purchase of FDA priority review vouchers from third parties, restructuring charges associated with streamlining global operations and COVID-19 related expenses.


      Beginning in the first quarter of 2022, the company includes acquired IPR&D and milestones expense in its reported non-GAAP financial measures. Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2021 included acquired IPR&D and milestones expense of $719 million on a pre-tax and $696 million on an after-tax basis, as well as other operating expense related to the Calico collaboration of $500 million on a pre-tax and after-tax basis, representing an unfavorable impact of $0.67 to both diluted EPS and adjusted diluted EPS.


      2.     The impact of the specified items by line item was as follows: 



      Nine Months Ended September 30, 2021

      (in millions)

      Cost of
      products
      sold


      SG&A


      R&D


      Other
      operating
      expense,
      net


      Other
      expense
      (income),
      net

      As reported (GAAP)

      $       13,126


      $         9,089


      $            5,095


      $                 432


      $            2,284

      Adjusted for specified items:










      Intangible asset amortization

      (5,912)


      —


      —


      —


      —

      Acquisition and integration costs

      (172)


      (275)


      (88)


      —


      —

      Change in fair value of contingent consideration                         

      —


      —


      —


      —


      (2,447)

      Litigation matters

      —


      (107)


      —


      —


      —

      Other

      (65)


      (50)


      (287)


      68


      15

      As adjusted (non-GAAP)

      $         6,977


      $         8,657


      $             4,720


      $                 500


      $              (148)


      3.     The adjusted tax rate for the first nine months of 2021 was 13.3 percent, as detailed below:







      Nine Months Ended September 30, 2021

      (dollars in millions)





      Pre-tax
      earnings


      Income taxes


      Tax rate

      As reported (GAAP)





      $              8,718


      $              1,214


      13.9 %

      Specified items





      9,320


      1,178


      12.6 %

      As adjusted (non-GAAP)





      $            18,038


      $              2,392


      13.3 %

      SOURCE AbbVie

      Modal title

      Also from this source

      Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

      Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from HARMONY IN DIVERSITY and HALO, two Phase 4 studies of aesthetic...

      Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

      Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

      Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.